|
|
 Previous Article | Table of Contents | Next Article 
Vitronectin Concentrates Proteolytic Activity on the Cell Surface
and Extracellular Matrix by Trapping Soluble Urokinase
Receptor-Urokinase Complexes
Triantafyllos Chavakis,
Sandip M. Kanse,
Barbara Yutzy,
H. Roger Lijnen, and
Klaus T. Preissner
From the Max-Planck-Institut, Kerckhoff-Klinik, Bad Nauheim, Germany;
and the Center for Molecular and Vascular Biology, Katholieke
Universiteit Leuven, Leuven, Belgium.
Urokinase-type-plasminogen activator (uPA) and its receptor are
localized in the vessel wall where they are involved in cellular activation and remodelling processes. Besides the cell surface glycolipid (GPI)-anchored urokinase receptor (uPAR), which binds uPA
with high affinity, recent evidence points to the existence of soluble
uPAR (suPAR), as well. In the present study, the origin, binding
mechanism, and cellular effects of suPAR were examined. Under basal
conditions human vascular smooth muscle cells (HVSMC), human umbilical
vein endothelial cells (HUVEC), and monocytic cells released 0.1 to 2 ng/mL suPAR, which was increased twofold to fivefold after phorbol
ester (PMA) stimulation, as measured by a function-dependent
enzyme-linked immunosorbent assay (ELISA). suPAR alone did not bind to
HVSMC or HUVEC, but reduced cellular uPA binding by 50% to 70%.
However, after removal of GPI-uPAR with phosphatidylinositol-specific
phospholipase C, suPAR dose-dependently increased uPA binding by
fourfold to fivefold. This increase in binding was completely inhibited
by vitronectin (VN) and by a monoclonal antibody against VN, but not by
other matrix proteins or antibodies. Thus, VN-mediated uPA binding to
cells was regulated by the ratio of soluble to surface-associated
uPAR. In a uPAR-deficient cell line (LM-TK ), suPAR
increased uPA binding up to 10-fold, whereas the truncated receptor
lacking the amino-terminal uPA-binding domain was ineffective. The
formation of a ternary uPA/suPAR/VN-complex on the cell surface and the
free extracellular matrix could be inhibited by a monoclonal antibody
against VN, as well as by plasminogen activator inhibitor-1 (PAI-1).
Moreover, VN-mediated binding of the uPA/suPAR-complex led to a
fivefold increase in plasminogen activator activity. Through this novel
pathway, VN concentrates the uPA/suPAR-complex to cell surfaces and
extracellular matrix sites, leading to the accumulation of plasminogen
activator activity required for cell migration and tissue remodelling
processes.
Blood, Vol. 91 No. 7 (April 1), 1998:
pp. 2305-2312
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. N. Athanasopoulos, D. Schneider, T. Keiper, V. Alt, U. R. Pendurthi, U. M. Liegibel, U. Sommer, P. P. Nawroth, C. Kasperk, and T. Chavakis
Vascular Endothelial Growth Factor (VEGF)-induced Up-regulation of CCN1 in Osteoblasts Mediates Proangiogenic Activities in Endothelial Cells and Promotes Fracture Healing
J. Biol. Chem.,
September 14, 2007;
282(37):
26746 - 26753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boncela, K. Smolarczyk, E. Wyroba, and C. S. Cierniewski
Binding of PAI-1 to Endothelial Cells Stimulated by Thymosin beta4 and Modulation of Their Fibrinolytic Potential
J. Biol. Chem.,
January 13, 2006;
281(2):
1066 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Chavakis, T. Keiper, R. Matz-Westphal, K. Hersemeyer, U. J. Sachs, P. P. Nawroth, K. T. Preissner, and S. Santoso
The Junctional Adhesion Molecule-C Promotes Neutrophil Transendothelial Migration in Vitro and in Vivo
J. Biol. Chem.,
December 31, 2004;
279(53):
55602 - 55608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nordengren, R. Pilka, V. Noskova, A. Ehinger, H. Domanski, C. Andersson, G. Hoyer-Hansen, S.R. Hansson, and B. Casslen
Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle
Mol. Hum. Reprod.,
September 1, 2004;
10(9):
655 - 663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, D. A. Lawrence, and L. Zhang
Sequences within Domain II of the Urokinase Receptor Critical for Differential Ligand Recognition
J. Biol. Chem.,
August 8, 2003;
278(32):
29925 - 29932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Duguez, M.-C. L. Bihan, D. Gouttefangeas, L. Feasson, and D. Freyssenet
Myogenic and nonmyogenic cells differentially express proteinases, Hsc/Hsp70, and BAG-1 during skeletal muscle regeneration
Am J Physiol Endocrinol Metab,
July 1, 2003;
285(1):
E206 - E215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shetty, K. Bdeir, D. B. Cines, and S. Idell
Induction of Plasminogen Activator Inhibitor-1 by Urokinase in Lung Epithelial Cells
J. Biol. Chem.,
May 9, 2003;
278(20):
18124 - 18131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dai, H. Guan, L. Liu, S. Little, G. McFadden, S. Vaziri, H. Cao, I. A. Ivanova, L. Bocksch, and A. Lucas
Serp-1, a Viral Anti-inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury
J. Biol. Chem.,
May 9, 2003;
278(20):
18563 - 18572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Pluskota, D. A. Soloviev, and E. F. Plow
Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration
Blood,
February 15, 2003;
101(4):
1582 - 1590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Chavakis, R. A. Pixley, I. Isordia-Salas, R. W. Colman, and K. T. Preissner
A Novel Antithrombotic Role for High Molecular Weight Kininogen as Inhibitor of Plasminogen Activator Inhibitor-1 Function
J. Biol. Chem.,
August 30, 2002;
277(36):
32677 - 32682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. CHAVAKIS, S. M. KANSE, R. A. PIXLEY, A. E. MAY, I. ISORDIA-SALAS, R. W. COLMAN, and K. T. PREISSNER
Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen
FASEB J,
November 1, 2001;
15(13):
2365 - 2376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gveric, R. Hanemaaijer, J. Newcombe, N. A. van Lent, C. F. M. Sier, and M. L. Cuzner
Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage
Brain,
October 1, 2001;
124(10):
1978 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Koolwijk, N. Sidenius, E. Peters, C. F. M. Sier, R. Hanemaaijer, F. Blasi, and V. W. M. van Hinsbergh
Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices
Blood,
May 15, 2001;
97(10):
3123 - 3131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Chavakis, S. M. Kanse, F. Lupu, H.-P. Hammes, W. Muller-Esterl, R. A. Pixley, R. W. Colman, and K. T. Preissner
Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions
Blood,
July 15, 2000;
96(2):
514 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. P. Dekkers, T. ten Hove, A. A. te Velde, S. J. H. van Deventer, and T. van der Poll
Upregulation of Monocyte Urokinase Plasminogen Activator Receptor during Human Endotoxemia
Infect. Immun.,
April 1, 2000;
68(4):
2156 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Sjoland, D. T. Eitzman, D. Gordon, R. Westrick, E. G. Nabel, and D. Ginsburg
Atherosclerosis Progression in LDL Receptor-Deficient and Apolipoprotein E-Deficient Mice Is Independent of Genetic Alterations in Plasminogen Activator Inhibitor-1
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2000;
20(3):
846 - 852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Mulligan-Kehoe, R. Wagner, C. Wieland, and R. Powell
A Truncated Plasminogen Activator Inhibitor-1 Protein Induces and Inhibits Angiostatin (Kringles 1-3), a Plasminogen Cleavage Product
J. Biol. Chem.,
March 9, 2001;
276(11):
8588 - 8596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
